But the patients in these reports do not seem to respond to treatment with either Oma or Cs-A alone but to treatment with a combined regimen; reflecting patients with high disease activity and possibly with two types of autoimmunity.19, 20, 21 Two types of autoimmunity existing together have been demonstrated in a recent clinical study by Asero et al.22who showed the co-existence of IgE and IgG autoantibodies to high- and low-affinity IgE receptors (FcεRI and FcεRII), tissue factor and thyroglobulin, particularly in late responders to omalizumab. The gene discussed is TG; the disease is Autoimmunity.